News

Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now
Biotech company Alnylam Pharmaceuticals conceded defeat for now in a lawsuit against Pfizer and BioNTech over technology in ...
Case filed against Pfizer for COVID vaccine marketing to be heard at state level
A case against one of the major COVID-19 vaccine providers filed by the Kansas Attorney General will be heard at the state ...
Drug Price Regulations: Is Pfizer Stock A Buy Or Sell?
Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...
Wondering if Pfizer's 7.6% Dividend Yield Is Sustainable? Here's What You Need to Know.
But when a dividend yield reaches ultrahigh levels, investors can feel a heightened level of uncertainty. Wondering if Pfizer ...
Trump’s Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks
Drugmakers' shares fell globally after President Trump said he would [sign an executive order]( ...
MedPage Today on MSN1d
Pfizer Confirms: Leading JAK Inhibitor Often Comes With Weight Gain
Patients taking tofacitinib (Xeljanz) in the drug's late-stage and post-marketing studies were more likely than those on ...
Explore more
Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer
Evaluate AbbVie Inc. vs. Pfizer Inc. amidst tariff disputes and drug pricing policies. Click for our comparison of ABBV and ...
Pfizer subsidiary receives A2 rating from Moody’s with stable outlook
Investing.com -- Moody’s Ratings has assigned an A2 rating to Pfizer Netherlands International Finance B.V. (PNIF BV), a ...
Jim Cramer on Pfizer (PFE) – “Caught in a Vortex, but I’m Sticking with Seagen and Dr. Bourla”
We recently published a list of 13 Stocks on Jim Cramer’s Radar Recently. In this article, we are going to take a look at ...